Search

A randomized thorough QT study was conducted to assess the effects of apomorphine sublingual film (SL‐APO) on corrected QT interval (QTc) and other cardiac conduction parameters in patients with Parkinson's disease (PD) and "OFF" episodes. Patients were titrated to an SL‐APO dose that resulted in FULL "ON," followed by up to two additional doses (maximum 60 mg), then randomized at the highest tolerated dose to a treatment sequence of SL‐APO, placebo, and moxifloxacin (400 mg, positive control) in a three‐way crossover design. Changes from baseline in time‐matched, placebo‐adjusted Fridericia‐corrected QTc interval (ΔΔQTcF) and Bazett‐corrected QTc interval (ΔΔQTcB) were analyzed from postdose electrocardiograms. Forty patients were randomized and received single doses of study treatments. Upper limits of 90% confidence intervals (CIs) for ΔΔQTcF of SL‐APO were below the 10‐millisecond regulatory threshold at all prespecified timepoints, demonstrating no clinically significant effect on QTcF. Lower limits of 90% CIs for ΔΔQTcF of moxifloxacin exceeded the 5‐millisecond regulatory threshold at all timepoints up to 3 hours, confirming assay sensitivity. SL‐APO had no clinically meaningful effects on QTcB, PR/QRS intervals, heart rate, or electrocardiogram‐derived morphology (EudraCT identifier: 2016‐001762‐29; ClinicalTrials.gov identifier: NCT03187301). [ABSTRACT FROM AUTHOR]

BIOGRAPHICAL SKETCHES EDWARD J. FARRAGHER is a professor of finance at Oakland University (Rochester, Michigan) He received a Ph.D. degree from the University of Illinois. His primary research interest is capital investment analysis in which he has published many articles in leading scholarly and professional journals. ROBERT T. KLEIMAN is a professor of finance at York University (Toronto, Ontario.) He received a Ph.D. degree from Michigan State University. He has published more than 50 articles on corporate finance, real estate investment, and international finance in leading scholarly and professional journals. He is an active consultant to many Fortune 500 companies. ANANDI P. SAHU is professor of economics at Oakland University, (Rochester, Michigan.) He received a Ph.D. degree from Washington University (St. Louis, Missouri.) He has published in a number of journals including the Southern Economic Journal, Financial Services Review, Quarterly Journal of Business and Economics, Review of Business and Economic Research, and Public Finance Quarterly. He is also the editor of two books on public policy., ABSTRACT Since the early l950s, the academic community has tried to convince corporate managers that there are sophisticated techniques that can improve the capital budgeting decision-making process. Over the years, [...]

Background: Interval duration measurements (IDMs) were compared between standard 12-lead electrocardiograms (ECGs) and 6-lead ECGs recorded with AliveCor's KardiaMobile 6L, a hand-held mobile device designed for use by patients at home. Methods: Electrocardiograms were recorded within, on average, 15 min from 705 patients in Mayo Clinic's Windland Smith Rice Genetic Heart Rhythm Clinic. Interpretable 12-lead and 6-lead recordings were available for 685 out of 705 (97%) eligible patients. The most common diagnosis was congenital long QT syndrome (LQTS, 343/685 [50%]), followed by unaffected relatives and patients (146/685 [21%]), and patients with other genetic heart diseases, including hypertrophic cardiomyopathy (36 [5.2%]), arrhythmogenic cardiomyopathy (23 [3.4%]), and idiopathic ventricular fibrillation (14 [2.0%]). IDMs were performed by a central ECG laboratory using lead II with a semi-automated technique. Results: Despite differences in patient position (supine for 12-lead ECGs and sitting for 6-lead ECGs), mean IDMs were comparable, with mean values for the 12-lead and 6-lead ECGs for QTcF, heart rate, PR, and QRS differing by 2.6 ms, -5.5 beats per minute, 1.0 and 1.2 ms, respectively. Despite a modest difference in heart rate, intervals were close enough to allow a detection of clinically meaningful abnormalities. Conclusions: The 6-lead hand-held device is potentially useful for a clinical follow-up of remote patients, and for a safety follow-up of patients participating in clinical trials who cannot visit the investigational site. This technology may extend the use of 12-lead ECG recordings during the current COVID-19 pandemic as remote patient monitoring becomes more common in virtual or hybrid-design clinical studies. [ABSTRACT FROM AUTHOR]

This paper evaluates the impact of defense and nondefense expenditures on inflation from 1960 to 1989. Using a closed economy IS-LM model with an expectations-augmented Phillips curve, a reduced form equation is derived and estimated for inflation. No significant relationship between growth in defense spending and the inflation rate is found. Unlike prior studies, nondefense spending is included in the analysis. The results suggest that growth in nondefense spending does not affect inflation significantly. This study reaffirms an earlier finding by Vitaliano that growth in defense expenditures has no influence on inflation., INTRODUCTION There is controversy surrounding the relationship between defense spending and inflation. The empirical analyses of Vitaliano (1984), Nourzad (1987), and Payne (1990) provide conflicting evidence about the impact of [...]

The time and effort devoted to the practice of investor relations has grown substantially in recent years.(1) In fact, a recent study of FORTUNE 500 chief financial officers found that [...]

This study evaluated the effect of enarodustat on cardiac repolarization in healthy subjects. Enarodustat (20 and 150 mg [supratherapeutic dose]), placebo, and moxifloxacin (positive control, 400 mg) were administered orally to males and females (N = 54) in a crossover fashion. Continuous 12‐lead Holter electrocardiogram (ECG) data were obtained before and after dosing, and blood samples were obtained for pharmacokinetic assessments of enarodustat, its circulating metabolite (R)‐M2, and moxifloxacin. Central tendency analysis was performed for relevant ECG parameters, the relationship between individual‐corrected interval from beginning of the QRS complex to end of the T wave in the frontal plane (QTcI, the primary end point) and plasma concentrations of enarodustat and (R)‐M2 were assessed, and ECG waveforms were evaluated for morphological changes. The supratherapeutic dose resulted in 7‐ and 9‐fold higher geometric mean maximum concentrations for enarodustat and (R)‐M2, respectively, than the 20 mg dose. Based on time point analysis, the upper bound of the 2‐sided 90% confidence interval (CI) for QTcI did not exceed 10 milliseconds at any of the time points for either dose. Based on QTcI‐concentration analysis, the slopes for enarodustat and (R)‐M2 were not statistically different than 0, and the upper bounds of the 2‐sided 90% CI for QTcI at the geometric mean maximum concentrations for the supratherapeutic dose were 1.97 and 1.68 milliseconds for enarodustat and (R)‐M2, respectively. The lower bound of the 2‐sided 90% CI for moxifloxacin was ≥5 milliseconds, demonstrating assay sensitivity. The study demonstrated no clinically relevant effect of enarodustat and (R)‐M2 on cardiac repolarization. There was no evidence of any clinically significant effect on the PR interval and QRS duration, and ECG waveforms showed no new clinically relevant morphological changes. [ABSTRACT FROM AUTHOR]